Aspire Biopharma Holdings, Inc. ASBP PHARMA
Company Overview
Aspire Biopharma Holdings, Inc., an early-stage biopharmaceutical company, develops and markets disruptive technology for novel sublingual delivery mechanisms in the United States. It offers sublingual aspirin product that is a soluble, PH neutral, and fast acting aspirin, which addresses cardiology emergencies and pain management. The company is also developing formulations for sublingually administered products, such as melatonin sleep-aid product; vitamins D, E, and K; testosterone; and semaglutide product. In addition, it is developing formulations for anti-nausea products, anti-psychotic products, ED drugs, seizure medication, and other classes of drugs through sublingual administration; and caffeine products, such as a formula for a single dose sublingual pre-workout supplement. The company was founded in 2021 and is headquartered in Estero, Florida.
Why Investors Should Care
Carries low leverage with a debt-to-equity ratio of 0.39.
Generates positive free cash flow, funding growth and shareholder returns internally.
Growth & Price Performance
Stock Price Performance
| 1 Year: | -44.55% |
| 6 Months: | +637.50% |
| 3 Months: | +33.08% |
| 1 Month: | +14.49% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)62.16 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Generates positive free cash flow.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Trading 62.5% below its 52-week high.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | ASBP Aspire Biopharma Holdings, Inc. PHARMA | 8.85 | -1.33 | $12.41M | 0.00% | - | - | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 28.35K |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 884 | 5.75K |
| Operating Income | - | - | - | - | - | - | - | - | - | - | -215.26K | - | -15.56M | - | -1.15M | -1.65M |
| Net Income | -2.38K | -15.31K | -87.83K | 120.69K | 1.08M | 2.87M | 1.81M | -69.26K | -230.97K | -96.92K | -216.27K | -765.71K | -15.94M | -1.98M | -1.85M | -3.22M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | -0.01 | - | -504.88 | - | -0.04 | -20.57 |
| R&D Expense | - | - | - | - | - | - | - | - | 10.50K | 10.50K | 7.00K | - | 263.09K | 352.89K | 207.90K | 296.72K |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | - | - | - | - | 6.20K |
| Gross Profit | - | - | - | - | -116 |
| Operating Income | - | - | - | -1.21M | -19.35M |
| Net Income | -25.48K | 3.34M | 4.46M | -1.31M | -24.48M |
| Diluted EPS | - | - | - | -1.90 | -16.38 |
| R&D Expense | - | - | - | 144.36K | 923.91K |
Balance Sheet (Annual)
Figures in USD.
| Metric | Feb 2021 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Total Assets | - | 293.22K | 300.18M | 19.98M | 147.99K | 1.31M |
| Total Equity | 0 | -475 | -9.94M | -487.86K | -1.54M | -6.38M |
| Total Liabilities | - | 293.70K | 11.12M | 403.33K | 1.69M | 7.69M |
| Current Liabilities | - | 293.70K | 303.32K | 403.33K | 1.69M | 7.59M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | -238.60K | -142.91K | 11.14K | -265.19K | -4.92M |
| Investing Cash Flow | - | -4.90M | 0 | 0 | - |
| Financing Cash Flow | 238.60K | 4.85M | 0 | 257.64K | 5.92M |
| Capital Expenditure | - | -4.90M | -75.90K | - | - |
| Free Cash Flow | - | -5.04M | 11.14K | -265.19K | -4.92M |
| Net Change in Cash | - | -185.46K | 11.14K | -7.54K | 1.00M |
| Share Buybacks | - | - | 284.92M | 13.78M | - |
Ratios (Annual)
Figures in %.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | -1.9% |
| Operating Margin % | - | - | - | - | -312,016.9% |
| Net Margin % | - | - | - | - | -394,725.1% |
| ROE % | 5,363.2% | -33.6% | -915.0% | 85.1% | 383.9% |
| ROCE % | - | - | - | 78.6% | 308.1% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Jane Street Group, LLC | 1.06% | 14.83K | $126.65K |
| 2 | Geode Capital Management, LLC | 0.75% | 10.47K | $89.45K |
| 3 | Vanguard Capital Management LLC | 0.74% | 10.41K | $88.88K |
| 4 | Vanguard Fiduciary Trust Co | 0.72% | 10.08K | $86.09K |
| 5 | Crewe Advisors LLC | 0.05% | 677 | $5.78K |
| 6 | Tower Research Capital LLC (TRC) | 0.02% | 283 | $2.42K |
| 7 | Toronto Dominion Bank | 0.01% | 166 | $1.42K |
| 8 | Avion Wealth | - | 45 | $384 |
| 9 | Valley Wealth Managers, Inc. | - | 33 | $281 |
| 10 | CrossingBridge Advisors, LLC | - | 20 | $170 |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for ASBP
Aspire Biopharma Holdings, INC. Announces Corporate Name Change To Aspire-Lakewood Holdings, Inc. - marketscreener.com
<a href="https://news.google.com/rss/articles/CBMi3wFBVV95cUxPa2hGZGE5YnlqQkRidjNvVXpkQVVkcFJvZ1VxTXllV05kV2RzNHBsTjJoeFBuT19tOFRIWTlyRkZwbE1DdnhNcU5Gck4tV1J1UWlHXzUtWmJ4SHVfSF9BSHpKc2dxNHJRV3pBTnp5SE5sQWJVaEdxUnB0THJ5WVJWbzhoeHRfMHRUVmdJcW…
ASBP Stock Jumps 21% On Buyback Offer – Retail Believes Every Dip’s A Buying Opportunity - Stocktwits
<a href="https://news.google.com/rss/articles/CBMingFBVV95cUxPTkFPNi13QkFjcVhEZldObFhOVGFkWXNpbERPaV9yeVNHamExNEk3VW5zejBuczZ6TGR0UzFuR0lHQjZPOVRrMG5RdFlTak53ZFlydUJ2OHdDS3VHR3hvVWVwbUJFczdCT0x1dzc2RFN3QzJwZFBTWnNSMGhVT3hPOUNwMnQ5Y3N5M2NTSj…
ASBP - Aspire Biopharma Holdings Inc Volatility & Greeks - Finviz
<a href="https://news.google.com/rss/articles/CBMiYEFVX3lxTE81a2dhMTV2TmR5Z1pDQnM2eU5iVEhQa2VyZ0UxYUtEeW1hZ010c3RKbVF2YzcxbU85RFFEQjJzcWNSZVBjRk1YTzV6RnpWNkZORmQwdy1ZR3djN2d6UERZdQ?oc=5" target="_blank">ASBP - Aspire Biopharma Holdings Inc …
Aspire Biopharma changes name to Aspire-Lakewood Holdings By Investing.com - Investing.com Canada
<a href="https://news.google.com/rss/articles/CBMiuAFBVV95cUxOOVR5TUtuSmE1X19pR2FlMDFkXzB3Z1daR1A3QnRoZGxUWERVVmR3eHNDUWZpcjVWUkpOTVg5dG96NkhIYW1yaDZWMDhVaEFnWlZCbXcybEg3X2I4Q2QtTV9kQkR5SDR1Y0NoVHAyMWRkM181SnhkSV80OVA3cVZmNE5XSWxpTWxlUU1CNj…
Aspire Biopharma puts 50 mg caffeine stick packs on Amazon - Stock Titan
<a href="https://news.google.com/rss/articles/CBMivwFBVV95cUxQa1VCaFpSS1VUUjJkUFpvNEQxa2VvVElxa1UtTUZqaDV5V3poRmZ4VExlNGRsQnc4cWV4REtQd29CZ1hMckhkUHo4dEVpVmtRNEJTV2lNaXpKT09rUnNjVHdfV24zaXVnQ1ZQRFpUX1c4UEdoa0pfLUY3R3JrRkUxMkhONTFwMVdjdmlHeV…
EXCLUSIVE: Aspire Biopharma Buys Its Way Into Global Auto Market With $30 Million DCS Deal - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMinAFBVV95cUxPZXNSRTk5ei1fYmlGSnZMNjE3RkhmRndZS2V4VE9oVGI1cGE3Q2ZqTHR2YWhtUGJnRG42SHJydDJqeTV5VmJUYWtZamVLdzY4ZjBYaUhhMGZSckZ2WFVQMGZFSnV6SnVZYzhrOFhWSEZrM1VINDNvb0hzRVFuaWo0M1FFX1B6N1MxeWFQd1…
ASBP — Frequently Asked Questions
What is the current share price of Aspire Biopharma Holdings, Inc. (ASBP)?
As of 2026-09-19 21:16 PDT, Aspire Biopharma Holdings, Inc. (ASBP) trades at $8.85 on NasdaqCM. Its 52-week range is $0.16 to $23.60.
What is the market capitalisation of ASBP?
Aspire Biopharma Holdings, Inc. (ASBP) has a market capitalisation of $12.41M on NasdaqCM.
What is the P/E ratio of ASBP?
ASBP trades at a trailing price-to-earnings (P/E) ratio of -1.33. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 0.95.
Is ASBP a good stock to buy?
This page provides a data-driven analysis of Aspire Biopharma Holdings, Inc. (ASBP), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.